Clinical Trial Update: Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma [Phase 2]

View source ↗

Summary

This clinical trial entry notes a Phase 2a study from Northwestern University evaluating ultrasound-based immune modulation for newly diagnosed glioblastoma, cu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Glioblastoma Idh-wildtype
• Gliosarcoma

Snippet

Sponsor: Northwestern University | Conditions: Newly Diagnosed Glioblastoma, Glioblastoma, Isocitric Dehydrogenase (IDH)-Wildtype | Phase 2 | Status: RECRUITING